Sickle cell patients are missing out on(错失，未能获得) an effective treatment despite widespread(广泛的，普遍的) US hospital access to the technology, new research has found.
新研究发现，尽管美国医院普遍拥有相关技术，镰状细胞病患者却无法获得一种有效的治疗。
That treatment is called a red blood cell exchange, a procedure that discards a patient’s damaged red blood cells while simultaneously mixing the patient’s remaining plasma, platelets and white blood cells with red blood cells from a donor before returning them to the body.(这种治疗叫做红细胞置换，该程序会丢弃患者受损的红细胞，同时将患者剩余的血浆、血小板和白细胞与来自捐献者的红细胞混合，然后再输回体内。)
这种治疗叫做红细胞置换，该程序会丢弃患者受损的红细胞，同时将患者剩余的血浆、血小板和白细胞与来自捐献者的红细胞混合，然后再输回体内。
But a new nationally representative survey of 100 US-based healthcare providers who actively manage at least one patient with sickle cell disease shows fewer than 3% of patients have been recorded receiving a red blood cell exchange even though 91% of surveyed providers report access to it.(但一项针对100名美国医疗提供者的全国代表性新调查显示，尽管91%的受访提供者报告能够获得红细胞置换，但记录在案接受该治疗的患者不到3%。)
但一项针对100名美国医疗提供者的全国代表性新调查显示，尽管91%的受访提供者报告能够获得红细胞置换，但记录在案接受该治疗的患者不到3%。这些提供者都至少管理着一名镰状细胞病患者。